Senior FDA official Vinay Prasad reportedly overrode his staff in deciding to reject Moderna's application for a new seasonal flu shot. Reading time 3 minutes The federal government’s crusade ...
Moderna said it plans to slash roughly 10% of its global workforce by the end of the year, as Covid shot sales continue to dwindle and the company grapples with uncertainty in the vaccine market. In ...
Add Yahoo as a preferred source to see more of our stories on Google. Moderna said the FDA's refusal was inconsistent with previous feedback from the agency. - Graham Hughes/Bloomberg/Getty Images ...
Matthew Herper covers medical innovation — both its promise and its perils. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...
Drug stock Moderna (MRNA) is pulling back to a historically bullish trendline and has plenty of contrarian signals flashing ...
Operator: Good day, and thank you for standing by. Welcome to the Moderna Second Quarter 2026 Conference Call. Please be ...
Phase 1 trial will evaluate safety and immune response for a strain of Ebola virus disease with no licensed vaccines ...
Moderna’s mRNA-based flu vaccine, mFlusiva, is approved by the Food and Drug Administration for adults aged 50 and over.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results